TY - JOUR
T1 - Biomarkers in GIST
T2 - Partly ready for prime-time use
AU - Blanke, Charles D.
PY - 2009/9/15
Y1 - 2009/9/15
N2 - Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.
AB - Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.
UR - http://www.scopus.com/inward/record.url?scp=70349463111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349463111&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-1563
DO - 10.1158/1078-0432.CCR-09-1563
M3 - Review article
C2 - 19737947
AN - SCOPUS:70349463111
SN - 1078-0432
VL - 15
SP - 5603
EP - 5605
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 18
ER -